KALA - KALA BIO, Inc.
Previous close
7.05
-0.010 -0.142%
Share volume: 200
Last Updated: Fri 27 Dec 2024 05:20:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$7.06
-0.01
-0.14%
Fundamental analysis
22%
Profitability
18%
Dept financing
21%
Liquidity
73%
Performance
15%
Performance
5 Days
4.00%
1 Month
-3.83%
3 Months
18.86%
6 Months
35.65%
1 Year
-18.00%
2 Year
59.18%
Key data
Stock price
$7.05
DAY RANGE
$7.06 - $7.16
52 WEEK RANGE
$4.79 - $9.25
52 WEEK CHANGE
-$16.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Mark T. Iwicki
Region: US
Website: kalarx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kalarx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.
Recent news